MCM
MDGL icon

Moore Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Moore Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,286
Closed -$603K – 507
2013
Q4 		$603K Buy
+3,286
New +$602K 0.01% 327

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Moore Capital Management's MDGL Position: Q1 2014 in Review

Moore Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2014, closing a stake of 3,286 shares — an estimated $603K sold.

Moore Capital Management first reported a position in MDGL in Q4 2013 and held it in 1 quarter. The position peaked at $603K in Q4 2013. 80 funds tracked by Wall St. Rank hold MDGL as of Q1 2014.

  • Moore Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Moore Capital Management sold 3,286 Madrigal Pharmaceuticals shares in Q1 2014, an estimated $603K.
  • Moore Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Moore Capital Management's Madrigal Pharmaceuticals position peaked at $603K in Q4 2013.
  • 80 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2014.

Based on Moore Capital Management's 13F filing for Q1 2014, filed 15 May 2014.